This financing will help MacroLux Medical expand its production capacity, accelerate new product development, and expand into global markets, driving rapid growth in the disposable endoscope field.
Founded in October 2020, MacroLux Medical's founding team comes from leading medical device companies both domestically and internationally, with over ten years of experience in the research and development of minimally invasive surgical products, global marketing, and production management. The company aims to become an innovative leader in endoscopic interventional therapy, with its core product, the disposable electronic endoscope, covering urology, respiratory, ICU, gynecology, digestion, and other fields, and has entered markets in China, the United States, Europe, and the Asia-Pacific region.
Endoscopic interventional therapy is widely used in fields such as digestion, urology, respiratory, ENT, and gynecology. Traditional reusable flexible endoscopes have issues such as cross-infection, high acquisition costs, and inefficiency. Disposable electronic endoscopes have emerged to effectively address the problem of cross-infection, ensuring that the endoscope is always in optimal condition, significantly improving surgical efficiency.
Additionally, disposable endoscopes can greatly reduce hospitals' procurement costs, promoting the dissemination and popularization of endoscopic diagnostic and therapeutic technologies. As a result, the penetration rate of disposable electronic endoscopes has rapidly increased in recent years, gradually replacing reusable endoscopes in certain departments.
The disposable electronic endoscope developed by MacroLux Medical excels in core performance areas such as image clarity and ease of operation, better meeting the needs of clinical doctors. Upon launch, it gained widespread recognition in the market, leading to continued investment from major institutions.
Martin Zhang, founder of MacroLux Medical, stated: "We are grateful for Yuanbio Venture Capital 's trust in MacroLux Medical, the ongoing support from our existing shareholders Legend Capital and Dalton Venture, and the assistance from our financing partner Haoyue Capital. The market for disposable electronic endoscopes is early-stage, clear, and rapidly growing. In just a few years, MacroLux Medical has established a product lineup of disposable electronic endoscopes for urology, respiratory, gynecology, and digestion, with leading product performance and broad recognition from customers and the industry. At the same time, we are quickly entering global markets, and the company is entering a phase of rapid growth. Ample funding support will help us further expand production capacity, accelerate new product development, and enhance global market expansion, providing more and better clinical solutions for customers worldwide."
Leimin Gu, partner at Yuanbio Venture Capital, remarked: "Minimally invasive medicine is an inevitable direction for the development of medical technology, leading the future of healthcare. Disposable endoscopes are not only essential tools for minimally invasive surgery but also represent a potential multi-billion-dollar market in the global healthcare sector. Yuanbio Venture Capital, with its forward-looking vision, has laid out numerous segments in the minimally invasive medical field, with particular emphasis on disposable endoscopes. In this field, MacroLux Medical has emerged as a shining star, thanks to its international perspective and rich experience. The team not only has a comprehensive endoscope technology R&D platform but also boasts a rich product pipeline and has formulated a unique global commercialization strategy. MacroLux Medical's ability to stand out in this competitive market is attributed not only to the team's strategic vision and execution but also to their firm determination and sense of mission for efficient execution. We feel incredibly honored to collaborate with the team led by Mr. Zhang Weiqiang and look forward to jointly promoting the development of more innovative products and accelerating their market introduction globally, bringing benefits to patients and healthcare providers worldwide."
Quan Zhou, Managing Director of Legend Capital, stated: "Congratulations to the company on completing this new round of financing and welcoming new partners. In less than two years of collaboration, the team has demonstrated professional and efficient operational capabilities, facilitating the company's anticipated transition from innovative product development to global commercialization. Disposable endoscopes represent an emerging market where Chinese companies are poised to lead globally, and we look forward to the company growing into a globally influential brand."
Ying Fu, Investment Director at Dalton Venture, expressed: "Dalton firmly believes that disposable electronic endoscopes are in a phase of rapid growth. As early investors in the previous two rounds, we have witnessed the company team's ability to respond quickly to market R&D demands, their strong supply chain integration capabilities, and excellent competitiveness in going global. We also look forward to MacroLux becoming a leader in the disposable endoscope market."
Yameng Ding, Founding Managing Partner and COO of Haoyue Capital, stated: "We are honored to assist MacroLux in completing this round of financing. MacroLux has a top-tier R&D and commercialization team, a global strategic plan, a differentiated endoscope R&D platform, and excellent mass production capabilities. We believe this financing will enhance MacroLux's R&D, production, and sales capabilities, laying a solid foundation for the company's future rapid development. We are optimistic about MacroLux and will grow alongside the company."
| About Yuanbio Venture Capital
Yuanbio Venture Capital is an investment institution focused on early-stage and growth-stage healthcare investments, based in Suzhou bioBAY and serving a global market. It has invested in over 180 excellent companies in the life and health sector, covering four main areas: new drug development, medical devices, in vitro diagnostics, and precision medicine, achieving substantial investment returns. Nineteen of these companies have listed on capital markets such as the Hong Kong Stock Exchange and the Sci-Tech Innovation Board. Yuanbio Venture Capital has been repeatedly recognized as one of the top ten venture capital funds in China's healthcare sector and one of the most active healthcare investment institutions. With a team of seasoned professional investors and top global scientific advisors, Yuanbio Venture Capital possesses rich entrepreneurial, venture capital, and corporate operation experience in the biopharmaceutical industry. With professionalism, focus, and abundant industry resources, we aim to become one of the most successful healthcare venture capital funds in China.
| About Legend Capital
Founded in April 2001, Legend Capital is a fund management company under Legend Holdings, focused on early-stage venture capital and growth-stage private equity investments. Over its twenty-year development, Legend Capital has adhered to international standards, creating best practices in fund operation and management. Through an active value-added service system, it promotes enterprise innovation and growth, continuously generating good investment returns while advancing industrial progress and social development in China. Legend Capital envisions becoming an internationally influential investment company and adheres to the core values of "prosperous and principled" while actively fulfilling social responsibilities. Legend Capital has long focused on investments in the medical device and diagnostics sectors, having invested in a number of leading companies in these subfields.
| About Dalton Venture
Dalton Venture focuses on early investments in the healthcare industry, with a particular emphasis on medical innovation technologies, and is an early investor in several domestically pioneering technology projects. The core team at Dalton comes from the healthcare industry and has successfully incubated early-stage startups and founded and managed publicly listed companies with market values exceeding 10 billion RMB. Dalton aims not just to be a value discoverer but also a value creator, accompanying and empowering companies through deep post-investment support. The firm has been recognized multiple times in the VC TOP 100 and Medical Device TOP 20 rankings.
| About Haoyue Capital
Founded in January 2014, Haoyue Capital is a leading investment bank focused on the healthcare industry in China. Headquartered in Shanghai, it has regional offices in Beijing and Shenzhen. Haoyue Capital is dedicated to leveraging capital and research to help outstanding companies in the Chinese healthcare sector successfully connect with capital markets and create added value for clients. The partner team at Haoyue Capital consists of seasoned investment bankers with years of experience in the Chinese healthcare sector. Haoyue Capital closely tracks market dynamics and investment trends in healthcare, covering various subfields, including innovative pharmaceuticals, medical devices, IVD and life sciences, healthcare services, and smart healthcare. As of 2023, Haoyue Capital has completed nearly 400 projects with a total transaction amount exceeding 10 billion USD; among them, over 50 mergers and acquisitions were completed, totaling over 5 billion USD. In 2023, Haoyue Capital completed nearly 50 complex transactions involving private financing, mergers and acquisitions, and services for listed companies, maintaining a comprehensive lead across various subfields in the healthcare industry.